Chondrogenically primed bone marrow derived mesenchymal stem cells (MSCs) have been shown to become hypertrophic and undergo endochondral ossification when implanted in vivo. Modulating this endochondral phenotype may be an attractive approach to engineering the osseous phase of an osteochondral implant. The objective of this study was to engineer an osteochondral tissue by promoting endochondral ossification in one layer of a bi-layered construct and stable cartilage in the other. The top-half of bi-layered agarose hydrogels were seeded with culture expanded chondrocytes (termed chondral layer) and the bottom half of the bi-layered agarose hydrogels with MSCs (termed osseous layer). Constructs were cultured in a chondrogenic medium for 21 days and thereafter were either maintained in a chondrogenic medium, transferred to a hypertrophic medium, or implanted subcutaneously into nude mice. This structured chondrogenic bi-layered co-culture was found to enhance chondrogenesis in the chondral layer, appearing to help re-establish the chondrogenic phenotype that is lost in chondrocytes during monolayer expansion. Furthermore, the bilayered co-culture appeared to suppress hypertrophy and mineralisation in the osseous layer.
Introduction
Articular cartilage has a limited capacity for self-renewal and repair. Damage to the articular surface can penetrate to the subchondral bone and such osteochondral defects are often associated with mechanical instability of the joint and warrant surgical intervention in order to prevent osteoarthritic degenerative changes [1] . Even in cases where lesions do not penetrate to the subchondral bone an osteochondral construct may be a more desirable implant as a bone-to-bone interface integrates better than a cartilage-to-cartilage interface [2] .
Autologous grafting procedures, such as mosaicplasty, are not ideal due to issues associated with topology conformity, donor site morbidity and tissue availability [3] . Tissue engineering applications aim to replace or regenerate damaged tissues through the combinations of cells, three-dimensional scaffolds and signalling molecules [4] [5] . A number of strategies have been implemented to engineer osteochondral constructs including bi-phasic scaffolding [6] [7] [8] [9] [10] [11] [12] , bioreactor technologies [13] [14] [15] [16] , and growth factor/gene delivery [17] [18] [19] [20] . Engineered anatomically accurate osteochondral grafts have also been suggested as a potential approach to joint condyle repair [21] [22] .
It is possible to engineer functional cartilaginous tissues by embedding chondrocytes in three dimensional hydrogels [23] [24] [25] [26] [27] . Well documented limitations associated with chondrocytes [28] [29] have led to increased interest in the use of mesenchymal stem cells (MSCs) for functional cartilage tissue engineering strategies [30] [31] [32] [33] [34] [35] [36] [37] . A major challenge in MSC based cartilage repair therapies is the prevention of terminal differentiation as maintenance of the chondrogenic phenotype is critical in order to ensure the long-term in vivo stability of a cartilaginous graft [38] . When implanted subcutaneously in nude mice chondrogenically primed MSCs fail to produce cartilage resistant to hypertrophy and endochondral ossification, unlike fully differentiated chondrocytes which are capable of producing stable cartilage in vivo [39] [40] .
This apparent obstacle in MSC based cartilage tissue engineering has recently been realised as a potential advantage in bone regeneration applications with chondrogenically primed bone marrow derived MSCs being used to engineer bone in vivo via endochondral ossification [41] [42] [43] . One rationale as to why the endochondral route may be superior to the traditional intramembranous process for bone regeneration is that hypertrophic chondrocytes are programmed to withstand the initial hypoxic conditions a tissue engineered graft will experience once implanted in vivo [44] . In contrast, osteogenically primed constructs often fail due to excessive in vitro mineralisation of the extracellular matrix inhibiting vascular invasion and the associated delivery of oxygen and nutrients into the engineered tissue [45] .
Another inherent advantage of chondrogenically primed MSCs for bone regeneration is that they are programmed to release factors that drive the mineralisation and vascularisation of the engineered tissue [44] . Modulating the endochondral phenotype of chondrogenically primed bone marrow derived MSCs may be an attractive approach to engineering the osseous phase of an osteochondral implant.
The objective of this study was to engineer an osteochondral tissue by promoting endochondral ossification in one layer of a chondrogenically primed bi-layered hydrogel and stable cartilage in another. Bi-layered hydrogels were fabricated by casting agarose seeded with chondrocytes (for the chondral layer) on top of agarose hydrogels seeded with MSCs (for the osseous layer). We hypothesised that by seeding the top layer of agarose hydrogels with chondrocytes and the bottom layer with bone marrow derived MSCs it would be possible to spatially restrict endochondral ossification to within the bottom layer both in vitro and in vivo following subcutaneous implantation in nude mice.
Materials and methods

Experimental design
This study consisted of three experiments. Experiment 1 investigated the synergistic effects of a structured co-culture of chondrocytes and bone marrow MSCs, comparing chondrogenesis and terminal differentiation in single layer chondrocyte-and MSC-seeded agarose hydrogels with a bi-layered agarose hydrogel where the top layer is seeded with chondrocytes and the bottom layer with MSCs. All constructs were maintained in a chondrogenic medium (CM) supplemented with transforming growth factor-β3 (TGF-β3) for a period of 49 days (further details below). No studies were undertaken to explore if differentiation could be induced in the absence of this growth factor. Experiment 2 investigated whether a hypertrophic medium could be used to engineer an osteochondral construct in vitro and involved culturing bi-layered agarose hydrogels in a CM for a period of 21 days after which constructs were either maintained in a CM for an additional 49 days, or transferred to a hypertrophic medium (HM) with (+) or without (-) β-glycerophosphate supplementation. Experiment 3 investigated the possibility of spatially regulating endochondral ossification in vivo. This involved culture of single layer MSC-seeded agarose hydrogels and bi-layered agarose hydrogels in a CM for a period of 21 days after which constructs were implanted subcutaneously in nude mice for an additional 28 days. The experimental design is illustrated in Fig. 1. 
Cell isolation and expansion
Chondrocytes and bone marrow derived MSCs were isolated from 4 month old porcine tissue as previously described [30] . Briefly, cartilage slices were rinsed with phosphate-buffered saline containing penicillin/streptomycin (100 U/mL) and digested by incubation with Dulbecco's modified Eagle's medium (DMEM) GlutaMax (Gibco, Biosciences, Dublin, Ireland) containing collagenase type II (315 U/mg; Worthington, Langanback Services) for 16-18 hours under constant rotation at 37°C. Bone marrow derived MSCs were isolated from the femoral shaft. The colony unit forming -fibroblastic (CFU-f) assay was performed as previously described [46] on freshly isolated MSCs to calculate the colony forming unit efficiency. Upon isolation chondrocytes and bone marrow derived MSCs were seeded at a density of 5x10 3 cells/cm 2 in 175 cm 2 T flasks, maintained in DMEM GlutaMax supplemented with 10% foetal bovine serum , 100 U/mL penicillin/streptomycin (both Gibco) and 5 ng/mL human fibroblast growth factor-2 (Prospec-Tany TechnoGene Ltd., Israel), and expanded to passage two (~ 11 population doublings for chondrocytes and 14 population doublings for MSCs).
Cell encapsulation in agarose hydrogels
Expanded chondrocytes and MSCs were separately suspended in 2% agarose (type VII;
Sigma-Aldrich) at ~40 °C and a density of 20x10 6 cells/mL and cast in a stainless steel mould to produce cylindrical (Ø5x3 mm) single-layered constructs. Bi-layered constructs (Ø5x3 mm) were fabricated by filling the bottom half (1.5 mm) of stainless steel moulds with MSC laden 2% agarose at ~40 °C and allowing the agarose cell suspension to set (termed osseous layer). Thereafter the top half of the mould was filled with chondrocyte laden 2% agarose at ~40 °C and left to set (termed chondral layer). The bottom surface of all bi-phasic constructs were cast on a hatch patterned poly-dimethyl-siloxane (PDMS) sheet so that both phases of the construct could be identified. All constructs were maintained in a chemically defined CM consisting of DMEM GlutaMAX supplemented with 100 U/mL penicillin/streptomycin (both Gibco), 100 μg/mL sodium pyruvate, 40 μg/mL L-proline, 50 μg/mL L-ascorbic acid-2-phosphate, 4.7 μg/mL linoleic acid, 1.5 mg/mL bovine serum albumine, 1×insulin-transferrin-selenium, 100 nM dexamethasone (all from Sigma-Aldrich) and 10ng/mL of human transforming growth factor-β3 (TGF-β3) (Prospec-Tany TechnoGene Ltd., Israel) for 21 days. In experiment 1 all constructs were maintained in a CM for a further 28 days. In experiment 2, bi-layered constructs were either maintained in a CM or transferred to a hypertrophic medium, which constituted the removal of TGF-β3, the addition of 1 nM Lthyroxine (Sigma-Aldrich) and a reduction in the level of dexamethasone to 1 nM, either with (HM+) or without (HM-) the supplementation of 20 μg/ml β-glycerophosphate (SigmaAldrich), for a further 28 days [47] .
In vivo subcutaneous transplantation
In experiment 3, following 21 days maintenance in a CM, single layer MSC-seeded constructs and bi-layered constructs were implanted subcutaneously into the back of nude mice (Balb/c; Harlan, Uk) as previously described [40] . Mice were euthanised 28 days after the surgery by CO 2 inhalation. The animal protocol was reviewed and approved by the ethics committee of Trinity College Dublin.
Biochemical analysis
Constructs were sliced in half transversely and digested with papain (125 µg/mL) in 0.1 M sodium acetate, 5mM L-cysteine-HCL, 0.05 M EDTA, pH 6.0 (all from Sigma-Aldrich) at 60 °C and 10 rpm for 18 h. DNA content was quantified using the Hoechst Bisbenzimide 33258 dye assay, with a calf thymus DNA standard. Proteoglycan content was estimated by quantifying the amount of sulphated glycosaminoglycan (sGAG) using the dimethylmethylene blue dye-binding assay (Blyscan, Biocolor Ltd., Northern Ireland), with a chondroitin sulphate standard. Total collagen content was determined by measuring the hydroxyproline content, using a hydroxyproline-to-collagen ratio of 1:7.69 [48] [49] . Briefly, samples were mixed with 38% hydrochloric acid (Sigma-Aldrich) and incubated at 110°C for 18 hours to allow hydrolysis to occur. Thereafter samples were dried in a fume hood overnight and the sediment re-suspended in ultra pure H 2 O. Chloramine T and 4-(Dimethylamino)benzaldehyde (both Sigma-Aldrich) reagents were added and the hydroxyproline content quantified with a trans-4-Hydroxy-L-proline (Fluka analytical) standard using a Synergy™ HT (BioTek Instruments, Inc) Multi-detection micro plate reader at a wavelength of 570 nm. 3-4 constructs were analysed per experimental group
Histology and immunohistochemistry
At each time point samples were fixed in 4% paraformaldehyde overnight, dehydrated in a graded series of ethanols, embedded in paraffin wax, sectioned at 5 μm and affixed to microscope slides. The sections were stained with 1% alcian blue 8GX in 0.1 M HCL to assess sGAG content, picro-sirius red to assess collagen distribution, and 1% alizarin red to assess calcium accumulation (all Sigma-Aldrich). Collagen types I, II and X were evaluated using a standard immunohistochemical technique; briefly, sections were treated with peroxidase, followed by treatment with chondroitinase ABC (Sigma-Aldrich) in a humidified environment at 37° C to enhance permeability of the extracellular matrix. Sections were incubated with goat serum to block non-specific sites and collagen type I (ab6308, 1:400; 1 mg/mL), collagen type II (ab3092, 1:100; 1 mg/mL) or collagen type X (ab49945, 1:200; 1.4 mg/mL) primary antibodies (mouse monoclonal, Abcam, Cambridge, UK) were applied for 1 hour at room temperature. Next, the secondary antibody (Anti-Mouse IgG biotin conjugate, 1:200; 2.1 mg/mL) (Sigma-Aldrich) was added for 1 hour followed by incubation with ABC reagent (Vectastain PK-400, Vector Labs, Peterborough, UK) for 45 min. Finally sections were developed with DAB peroxidase (Vector Labs) for 5 min. Positive and negative controls were included in the immunohistochemistry staining protocol for each batch.
Micro-computed tomography
Micro-computed tomography (μCT) scans were carried out on the in vivo specimens in order to quantify mineral content. A Scanco Medical 40 μCT system (Scanco Medical, Bassersdorf, Switzerland) was used for evaluation with a 70 kVp X-ray source and 114 μA. 3 constructs were analysed per experimental group.
Statistical analysis
All statistical analyses were carried out using Minitab 15.1. Results are reported as mean ± standard deviation. Groups were analysed by a general linear model for analysis of variance with groups of factors. Tukey's test was used to compare conditions. Significance was accepted at a level of p < 0.05. (Fig. 2) , the chondral layer of bi-layered constructs stained more intensely for picro-sirius red compared to single layer chondrocyte constructs and the osseous layer stained weaker for picro-sirius red compared to single layer MSC constructs.
Results
A structured bi-layered co-culture enhances chondrogenesis in the chondral
Immunohistochemical analysis demonstrated stronger staining for type II collagen in the chondral layer of the bi-layered constructs compared to single layer chondrocyte constructs and weaker staining for type X collagen in the osseous layer compared to single layer MSC constructs, see Fig. 4 . In general all constructs stained weakly for collagen type I accumulation.
A hypertrophic medium induces in vitro mineralisation of the osseous layer of bi-layered constructs
No evidence of mineralisation was observed in bi-layered constructs maintained in a hypertrophic medium without additional β-glycerophosphate supplementation (HM-). When 
Endochondral ossification can be spatially regulated in vivo
Prior to subcutaneous implantation in nude mice both bi-layered and single layer MSC (Fig. 6 (b) ), was significantly greater for single layer MSC constructs compared to bi-layered constructs (6.09 ± 0.59 vs. 1.36 ± 0.42 mm 3 ; n=3; p<0.001).
Bi-layered constructs weakly stained for collagen types I and X prior to implantation, 
Discussion
This study examined the effect of a structured bi-layered co-culture on chondrogenesis of chondrocytes and bone marrow derived MSCs seeded in agarose hydrogels and tested the hypothesis that it is possible to engineer an osteochondral construct in vivo through spatial regulation of endochondral ossification. In vitro a structured bi-layered co-culture enhanced and MSCs has also been shown to enhance proliferation of chondrocytes [54, 56] , although such a phenomena was not observed in our bi-layered co-culture system. Direct cell to cell interaction may be required to drive the enhanced proliferation of chondrocytes when cocultured with MSCs [56] , which is absent in our culture model as cells are separately encapsulated in the different regions of the hydrogel.
Even in a chondrogenic medium, single layer MSC seeded constructs tended to mineralise around their periphery. Previous studies have demonstrated that a higher oxygen tension exists in this region [57] , with such high oxygen tensions known to enhance mineralisation of engineered cartilaginous constructs [46] . To accelerate such mineralisation, hypertrophic cartilaginous templates can be supplemented with β-glycerophosphate [47] .
When bi-layered constructs were transferred to a hypertrophic medium supplemented with β-glycerophosphate, mineralisation of the MSC layer occurred whereas the chondrocyte seeded layer remained resistant to mineralisation. In hypertrophic media formulations, both with and without β-glycerophosphate supplementation, elongation of the interface between the two cell types was observed, suggesting perhaps that aspects of long bone growth are being mimicked in this culture system. The large reduction in DNA content in the mineralised phase of our bilayered construct cultured in the presence of β-glycerophosphate is also representative of endochondral bone formation where hypertrophic chondrocytes undergo apoptotic cell death [58] .
Chondrogenically primed bone marrow derived MSCs have been shown to produce bone in vivo via endochondral ossification [41] [42] [43] . When implanted subcutaneously into nude mice the MSC layer of bi-layered constructs proceeded along the endochondral route with mineralisation progressing from the bottom of the construct. Previous studies exploring the fate of chondrogenically primed MSC pellets within a subcutaneous environment have observed a mineralised peripheral collar surrounding an inner cartilaginous region after 4
weeks in vivo which became almost completely resorbed by bone after 8 weeks in vivo [41] .
Therefore the 4 week in vivo time point in our study may not have been sufficient to achieve complete endochondral ossification of the ossesous layer of the bi-layered constructs (see A critical question that remains to be answered is how this process of endochondral ossification would proceed within such a bi-layered construct within a defect of a load bearing joint. The subcutaneous environment differs in a number of notable ways to the orthotopic environment. Mechanical cues, absent in the subcutaneous environment, such as hydrostatic pressure [59] [60] and dynamic compression [61] [62] have been shown to play a role in regulating the endochondral phenotype of MSCs as well as matrix production [63] .
The evolving intrinsic properties of the extracellular matrix may also play a role in driving this differentiation pathway [64] . Furthermore, the subcutaneous environment is well vascularised, which differs from the low oxygen microenvironment of articular cartilage. A low oxygen environment has been shown to suppress hypertrophy and markers of endochondral ossification in chondrogenically primed MSCs [46] . How such cues are integrated to regulate cell fate is a key question that needs to be addressed to enable any putative MSC-based therapy to be successfully used in the treatment of damaged and diseased joints.
Scaling-up of engineered grafts, and the associated nutrient diffusion and waste removal limitations, is a major challenge that will need to be overcome if the proposed engineered constructs are to be used in the treatment of large joint defects. Motivated by the fact that no biological based therapies exist to treat patients with osteoarthritis a number of studies have investigated engineering anatomically accurate osteochondral grafts for joint condyle repair [21] [22] [65] [66] . The endochondral approach described in this study may be a powerful tool in scaling-up the osseous phase of such grafts as it is possible to engineer large cartilaginous grafts in vitro using MSCs as the low oxygen conditions that develop within these constructs supports chondrogenic differentiation and the functional development of the engineered tissue [57] . Future studies in our lab will explore the potential of the proposed bilayered constructs to treat large scale osteochondral defects within the articular surface of load bearing joints.
Conclusions
In a structured bi-layered chondrogenic co-culture of chondrocytes and MSCs, chondrogenesis is enhanced in the chondrocyte seeded layer while hypertrophy and mineralisation is inhibited in the MSC seeded layer. Mineralisation of the osseous layer of such a bi-layered construct can be induced in vitro through culture in a hypertrophic medium supplemented with β-glycerophosphate or in vivo following subcutaneous implantation.
Implanting chondrogenically primed bi-layered constructs containing chondrocytes and
MSCs and spatially regulating endochondral ossification in vivo represents a promising new approach for the treatment of osteochondral defects. 
